RE:RE:RE:RE:Vaccine That is quite important as the company's valuation will be based on the R&D success going forward, if and when they get the nod from the agencies it will be business as usual in a COVID free world.
In terms of timing it is also perfect as by the time they start the process the vaccine should have been distributed for a while some time in Q1/Q2 2021.
qwerty22 wrote: also removes some uncertainty about recruitment for next years trials.
SPCEO1 wrote: As life gets back to normal, which is still quite a ways off, that should help the sales of Trogarzo very minimally and Egrifta to a larger extent. But the stock really should not be too impacted by that as the real catalysts for the stock at this point should be developments on the R&D front. Not that any of us would complain about improve sales though.
ggg088 wrote: Any impact on Th?